CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock Price, Forecast & Analysis
NASDAQ:CNTB • KYG235491019
CNTB Key Statistics, Chart & Performance
The current stock price of CNTB is 2.47 USD. In the past month the price decreased by -3.14%. In the past year, price increased by 171.46%.
CNTB Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CNTB. When comparing the yearly performance of all stocks, CNTB is one of the better performing stocks in the market, outperforming 95.13% of all stocks.
CNTB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNTB. While CNTB seems to be doing ok healthwise, there are quite some concerns on its profitability.
CNTB Financial Highlights
Over the last trailing twelve months CNTB reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS increased by 74.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.2% | ||
| ROE | -28.22% | ||
| Debt/Equity | 0 |
CNTB Forecast & Estimates
11 analysts have analysed CNTB and the average price target is 8.06 USD. This implies a price increase of 226.23% is expected in the next year compared to the current price of 2.47.
For the next year, analysts expect an EPS growth of -212.62% and a revenue growth -99.83% for CNTB
CNTB Ownership
CNTB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.98 | 397.113B | ||
| AMGN | AMGEN INC | 17.23 | 204.262B | ||
| GILD | GILEAD SCIENCES INC | 16.7 | 178.373B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.37 | 121.819B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.83 | 81.488B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.7 | 43.76B | ||
| INSM | INSMED INC | N/A | 31.99B | ||
| NTRA | NATERA INC | N/A | 30.068B | ||
| BIIB | BIOGEN INC | 12.61 | 27.594B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.1 | 21.685B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CNTB
Company Profile
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 62 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Company Info
CONNECT BIOPHARMA HOLDINGS L
3580 Carmel Mountain Road, Suite 200
San Diego CALIFORNIA 215400 US
CEO: William Pan
Employees: 62
Phone: 18587271040
CONNECT BIOPHARMA HOLDINGS L / CNTB FAQ
Can you describe the business of CONNECT BIOPHARMA HOLDINGS L?
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 62 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
What is the current price of CNTB stock?
The current stock price of CNTB is 2.47 USD. The price decreased by -1.98% in the last trading session.
Does CNTB stock pay dividends?
CNTB does not pay a dividend.
What is the ChartMill rating of CONNECT BIOPHARMA HOLDINGS L stock?
CNTB has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists CNTB stock?
CNTB stock is listed on the Nasdaq exchange.
What do analysts say about CONNECT BIOPHARMA HOLDINGS L (CNTB) stock?
11 analysts have analysed CNTB and the average price target is 8.06 USD. This implies a price increase of 226.23% is expected in the next year compared to the current price of 2.47.
Can you provide the short interest for CNTB stock?
The outstanding short interest for CONNECT BIOPHARMA HOLDINGS L (CNTB) is 0.84% of its float.